Price T Rowe Associates Inc Alaunos Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.43 - $0.65 $5,948 - $8,992	-13,834 Reduced 10.18%	122,000 $63,000
Q1 2023 May 15, 2023	BUY	$0.46 - $0.81 $21,758 - $38,313	47,300 Added 53.43%	135,834 $86,000
Q3 2022 Nov 14, 2022	SELL	$1.04 - $322.5 $11,300 - $3.5 Million	-10,866 Reduced 10.93%	88,534 $153,000
Q2 2022 Aug 15, 2022	SELL	$0.41 - $1.24 $13,298 - $40,220	-32,436 Reduced 24.6%	99,400 $123,000
Q1 2022 May 16, 2022	BUY	$0.62 - $1.17 $11,098 - $20,943	17,900 Added 15.71%	131,836 $86,000
Q4 2021 Feb 14, 2022	SELL	$1.09 - $1.89 $126,985 - $220,185	-116,500 Reduced 50.56%	113,936 $124,000
Q3 2021 Nov 15, 2021	BUY	$1.44 - $2.73 $183,600 - $348,075	127,500 Added 123.86%	230,436 $419,000
Q2 2021 Aug 16, 2021	BUY	$2.63 - $3.67 $21,910 - $30,574	8,331 Added 8.81%	102,936 $272,000
Q1 2021 May 17, 2021	SELL	$2.82 - $5.6 $37,644 - $74,754	-13,349 Reduced 12.37%	94,605 $341,000
Q4 2020 Feb 16, 2021	BUY	$2.09 - $3.09 $225,623 - $333,577	107,954 New	107,954 $272,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $404M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.